TC Biopharm (Holdings) WTS (TCBWF) Financials
Newest figures come from the filing for FY2024, filed May 9, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TCBWF SEC filings page.
This page shows TC Biopharm (Holdings) WTS (TCBWF) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings.
Financial Health Signals
We do not publish a peer-relative financial health score for TC Biopharm (Holdings) WTS, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
TC Biopharm (Holdings) WTS passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). No profitability signals pass, 1 of 2 leverage/liquidity signals pass.
TC Biopharm (Holdings) WTS reported a net loss of $15.2M while operations used $15.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
TC Biopharm (Holdings) WTS's EBITDA was -$15.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. The change from the prior year is not meaningful, because that figure was zero or negative.
TC Biopharm (Holdings) WTS reported a net loss of $15.2M in fiscal year 2024. The change from the prior year is not meaningful, because that figure was zero or negative.
TC Biopharm (Holdings) WTS earned -$0.04 per diluted share (EPS) in fiscal year 2024.
Not reported for fiscal year 2024.
Cash & Balance Sheet
TC Biopharm (Holdings) WTS recorded an outflow of $15.8M in free cash flow in fiscal year 2024, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.
TC Biopharm (Holdings) WTS held $1.5M in cash as of fiscal year 2024; no long-term debt figure is on record for that period.
Not reported for fiscal year 2024.
Margins & Returns
TC Biopharm (Holdings) WTS's ROE was -403.8% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 183.9 percentage points from the prior year.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Capital Allocation
TC Biopharm (Holdings) WTS invested $6.7M in research and development in fiscal year 2024. This represents a decrease of 32.1% from the prior year.
TC Biopharm (Holdings) WTS invested $80K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 43.4% from the prior year.
Not reported for fiscal year 2024.
TCBWF Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY24Filing | FY23Filing | FY22Filing |
|---|---|---|---|
| Revenue | N/A | N/A | $4.6M |
| R&D Expenses | $6.7M-32.1% | $9.9M+8.0% | $9.2M |
| SG&A Expenses | $9.3M+12.4% | $8.2M-2.9% | $8.5M |
| Operating Income | -$16.0Mn/m | -$18.1Mn/m | -$14.6M |
| EBITDA | -$15.4Mn/m | -$17.3Mn/m | -$13.7M |
| Interest Expense | N/A | $106K-98.7% | $8.2M |
| Income Tax | -$816Kn/m | -$1.4Mn/m | -$2.1M |
| Net Income | -$15.2Mn/m | -$7.5Mn/m | -$1.6M |
| EPS (Basic) | -$0.04 | -$1.22 | -$2.31 |
| EPS (Diluted) | -$0.04 | -$1.22 | -$2.31 |
| Diluted Shares (Avg) | 377M | 6M | 687,199 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
TCBWF Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY24Filing | FY23Filing | FY22Filing |
|---|---|---|---|
| Total Assets | $10.4M-8.4% | $11.4M-16.5% | $13.6M |
| Current Assets | $7.2M-0.5% | $7.3M-19.2% | $9.0M |
| Cash & Equivalents | $1.5M-51.5% | $3.1M-46.0% | $5.8M |
| Short-Term Investments | $0n/m | $0n/m | $0 |
| Long-Term Investments | $0n/m | $0n/m | $0 |
| Total Liabilities | $6.7M-16.3% | $8.0M-39.9% | $13.2M |
| Current Liabilities | $5.2M-14.2% | $6.1M-45.3% | $11.1M |
| Non-Current Liabilities | $1.5M-23.1% | $1.9M-12.2% | $2.2M |
| Total Equity | $3.8M+10.1% | $3.4M+755.3% | $400K |
| Retained Earnings | -$65.8Mn/m | -$51.5Mn/m | -$40.3M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
TCBWF Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY24Filing | FY23Filing | FY22Filing |
|---|---|---|---|
| Operating Cash Flow | -$15.7Mn/m | -$13.4Mn/m | -$18.5M |
| Depreciation & Amortization | $544K-32.6% | $807K-13.2% | $929K |
| Stock-Based Compensation | $1.3M+124.1% | $566K-58.2% | $1.4M |
| Capital Expenditures | $80K-43.4% | $141K-51.6% | $291K |
| Free Cash Flow | -$15.8Mn/m | -$13.6Mn/m | -$18.8M |
| Investing Cash Flow | -$116Kn/m | -$266Kn/m | -$375K |
| Financing Cash Flow | $14.4M+32.2% | $10.9M-51.8% | $22.5M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TCBWF Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY24Filing | FY23Filing | FY22Filing |
|---|---|---|---|
| Operating Margin | N/A | N/A | -314.3% |
| Net Margin | N/A | N/A | -34.2% |
| Return on Equity | -403.8%-183.9pp | -220.0%+176.6pp | -396.5% |
| Return on Assets | -145.9%-79.8pp | -66.1%-54.5pp | -11.6% |
| Current Ratio | 1.39+0.2x | 1.20+0.4x | 0.81 |
| Liabilities-to-Equity | 1.77-0.6x | 2.33-30.8x | 33.09 |
| Asset Turnover | N/A | N/A | 0.34 |
| FCF Margin | N/A | N/A | -404.0% |
Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, FCF Margin.
Where TC Biopharm (Holdings) WTS Ranks
Frequently Asked Questions
No, TC Biopharm (Holdings) WTS (TCBWF) reported a net loss of $15.2M in fiscal year 2024.
TC Biopharm (Holdings) WTS (TCBWF) had EBITDA of -$15.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
TC Biopharm (Holdings) WTS (TCBWF) has a return on equity of -403.8% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
TC Biopharm (Holdings) WTS (TCBWF) recorded an outflow of $15.8M in free cash flow during fiscal year 2024. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
TC Biopharm (Holdings) WTS (TCBWF) recorded an outflow of $15.7M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
TC Biopharm (Holdings) WTS (TCBWF) had $10.4M in total assets as of fiscal year 2024, including both current and long-term assets.
TC Biopharm (Holdings) WTS (TCBWF) invested $80K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
TC Biopharm (Holdings) WTS (TCBWF) invested $6.7M in research and development during fiscal year 2024.
TC Biopharm (Holdings) WTS (TCBWF) had a current ratio of 1.39 as of fiscal year 2024, which is considered adequate.
TC Biopharm (Holdings) WTS (TCBWF) had a liabilities-to-equity ratio of 1.77 as of fiscal year 2024, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2024, because the filing data we hold for that year carries no long-term debt figure.
TC Biopharm (Holdings) WTS (TCBWF) had a return on assets of -145.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
TC Biopharm (Holdings) WTS (TCBWF) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
TC Biopharm (Holdings) WTS (TCBWF) reported a net loss of $15.2M while operations used $15.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.